The human B-cell receptor repertoire constitutes an invaluable resource for discovery of therapeutic antibodies 1,2 . Cloning from individual B cells obtained via immortalization and expansion in vitro, or from single B cells obtained by limiting dilution or fluorescence-activated cell sorting (FACS), has been used extensively to discover anti-infective antibodies, including broadly neutralizing antibodies (bNAbs) to HIV-1 and influenza 3,4 . In parallel, over the last 25 years the screening of combinatorial libraries generated by random pairing of amplified V H and V L genes from human B cells has yielded numerous antibodies, leading to dozens of experimental or approved drug products 5,6 . However, single-cell cloning is time-and resource-intensive, and is therefore limited to analysis of a small fraction of the human antibody repertoire 7,8 , whereas combinatorial library screening has the capacity to interrogate functional interrogation and mining of natively paired human V H :V L antibody repertoires ,9-11 We gratefully acknowledge B. Hartman for assistance with figures, N. Doria-Rose, G. Ippolito, and M. Kanekiyo for advice and guidance, S. Lucas, and K. Zhou for help with experiments, S. Darko for assistance with data processing, and E. Shusta and S. Harrison for kindly sharing reagents and research tools.
We present a technology to screen millions of B cells for natively paired human antibody repertoires. Libraries of natively paired, variable region heavy and light (V H :V L ) amplicons are expressed in a yeast display platform that is optimized for human Fab surface expression. Using our method we identify HIV-1 broadly neutralizing antibodies (bNAbs) from an HIV-1 slow progressor and high-affinity neutralizing antibodies against Ebola virus glycoprotein and influenza hemagglutinin.
antibody function from millions of B cells. However, the non-cognate pairing of V H and V L sequences in these libraries frequently gives rise to antibodies with lower selectivity and inferior biophysical properties compared to authentic human immunoglobulins 9, 10 .
We report a technology for large-scale functional interrogation of the natively paired V H :V L antibody repertoire ( Fig. 1) . Because V H and V L genes are encoded by separate mRNA transcripts, they are first physically linked into a single amplicon for subsequent cloning into an expression vector. V H and V L linkage is accomplished by a two-step single-cell emulsion lysis and oligo-dT capture of V H and V L mRNAs from the same B cell, followed by a second reverse transcription (RT) and overlap-extension (OE)-PCR step to create contiguous V H :V L amplicons 11, 12 . In these amplicons the V H and V L genes are joined through a linker designed to enable one-step sub-cloning into a yeast Fab surface-expression vector, whereby the V H and V L genes are transcribed from a galactose-inducible bidirectional promoter with C H1 (human IgG1 isotype) and C L (human κ and λ2 isotypes) at the C terminus of the V H and V L , respectively ( Fig. 1a,b, Supplementary  Fig. 1 and Supplementary Table 1 ).
Human antibodies often express poorly in microbial hosts 13 , and while expression efficiency in yeast is substantially higher relative to Escherichia coli or phage [13] [14] [15] , examination of a panel of 13 previously reported human influenza hemagglutinin (HA)-specific antibodies revealed that only 7/13 antibodies (53%) bound antigen when displayed on yeast ( Fig. 1c and Supplementary Fig. 2 ) 16 . Consistent with earlier reports 17 , co-expression of protein disulfide isomerase (PDI) increased display efficiency, as monitored by two-color flow cytometry, to 10/13 antibodies (Fig. 1c) . In addition to PDI expression, the enhanced dimerization of heavy and light chains via fusion to C-terminal leucine-zipper domains resulted in the display of the full set of 13/13 human anti-HA antibodies ( Fig. 1c and Supplementary  Fig. 2 ) 18 . We then tested the display efficiency of three other human antibodies (two anti-Ebola virus (EBOV) antibodies: c13c6 and KZ52, and the anti-HIV-1 bNAb N123-VRC34.01 that targets the HIV-1 fusion peptide 19 ). All three antibodies displayed efficiently and were shown to bind selectively to their respective antigens in the optimized system ( Supplementary Fig. 2) . Extensive earlier studies demonstrated that yeast display enables interrogation of the human antibody repertoire based on affinities or off-rates, for epitope specificity, and for other properties including stability 15 (Fig. 1d) . Clones of interest can then be expressed either as Fab or as IgG for detailed functional and biochemical assays ( Fig. 1d) .
We used this approach to analyze the antibody repertoire of an individual 6 d after immunization with an experimental EBOV vaccine 20 .
This peak plasmablast V H :V L repertoire was displayed in yeast, and cells were analyzed and sorted for binding to EBOV mucin-like domain deleted glycoprotein (GP ∆muc ). We used high-throughput sequencing (HTS) to track antibody lineages throughout the screening process. Of 1,189 unique CDRH3:CDRL3 nucleotide clusters obtained from 5,002 plasmablasts after highly stringent sequence quality filtering, 828 were verified as cloned and displayed in the system using HTS (70% overall efficiency for library construction and display). As expected for the peak post-vaccination plasmablast response, an appreciable (6%) fraction of repertoire-expressing yeast cells in the pre-sort library bound to antigen, and antigen-specific clones were highly enriched after the third round of sorting ( Fig. 2a and Supplementary Fig. 3 ). Single-colony analysis of yeast yielded seven antibody lineages that bound to GP ∆muc (EBOV.YD.01-EBOV. YD.04, EBOV.YD.09-EBOV.YD.11; Supplementary Table 2 and Supplementary Fig. 4 ). Comparison of HTS data sets for the presort library and the sorted library after three rounds of screening revealed that all seven clones isolated above had been enriched by ≥120-fold. Four of these antibodies were randomly selected (EBOV. YD.01-EBOV.YD.04) and expressed as IgG1s in HEK293 cells, then digested to generate Fabs, which were shown to bind GP ∆muc with nM affinities by biolayer interferometry (BLI) ( Supplementary  Fig. 5 and Supplementary Table 2 ). All four antibodies blocked infection by EBOV GP-pseudotyped lentiviral particles, with neutralization ranging from 55% to 99% at 10 µg/ml ( Fig. 2b and Supplementary  Fig. 6 ). Competition assays revealed that these antibodies targeted distinct non-overlapping epitopes (Fig. 2c) . EBOV.YD.03 competed with the well-characterized neutralizing antibody KZ52, indicating that it binds an epitope similar to antibodies generated during natural infection 21 (Fig. 2c) .
HTS surveillance of antibody clonal prevalence during screening enabled us to retrieve other antibodies that were enriched across rounds, but not identified by single-colony picking. We synthesized four additional antibody lineages that had been enriched more than eightfold in HTS data sets after multiple rounds of FACS. Three out of four antibodies identified by HTS bound to GP ∆muc with singledigit nM K D (EBOV.YD.06-EBOV.YD.08; Supplementary Fig. 5 and Supplementary Table 2 ) while another clone, EBOV.YD.05, bound weakly (~3 µM K D as a Fab).
We then applied this yeast display technology to assess an antibody lineage in an HIV-1-infected donor. Kong and co-workers recently identified N123-VRC34, an HIV-1 bNAb lineage that binds to the fusion peptide (FP) 19 . We interrogated the antibody repertoire of 1.42 million peripheral B cells from this donor (N123) and amplified the V H :V L repertoire with a unique human FR1 primer set that was also supplemented with lineage-specific primers. Only the inclusion of lineage-specific primers enabled us to successfully recover the N123-VRC34 lineage, which contains several reported FR1 mutations ( Supplementary Tables 3 and 4 ) and is extremely rare at this time point within the donor (roughly 0.003% of all B cells 19 ). Yeast libraries were sorted using an epitope protein scaffold containing the eight terminal AA of the fusion peptide (VRC34-epitope scaffold-FP-APC) and a version of the scaffold alone without the fusion peptide (VRC34-epitope scaffold-KO-PE) 19 . As with EBOV antibody libraries, the HIV-1 antibody libraries were highly enriched for FP-specific clones by the third round of sorting ( Fig. 2d and Supplementary Fig. 7) .
HTS revealed that after three rounds of screening, VRC34-lineage antibodies far outcompeted other antibody lineages, constituting 98.7% of high-quality sequences and suggesting that the VRC34 lineage dominated the FP-specific repertoire in this donor. Three prevalent V H :V κ clones were expressed and the respective Fabs were shown to bind to the HIV-1 fusion peptide probe with high affinity ( Fig. 2f and Supplementary Fig. 8 ). To further "bin" FP-binding clones based Affinity: b r i e f c o m m u n i c at i o n s on affinity, we gated the yeast population during the third round of sorting by increasing fluorescence intensity to FP; Fabs of four clones restricted to a high-, medium-, or low-affinity gated population had K D values consistent with their respective FACS profile ( Fig. 2e,f and Supplementary Fig. 8 ). In total, seven unique VRC34 lineage antibodies were identified and all were broadly neutralizing ( Supplementary  Fig. 9 ). Notably, three double-nucleotide changes within a codon were observed that resulted in nonsynonymous amino acid substitutions, which are highly unlikely to have resulted from PCR or other artifacts and thus likely arose from somatic hypermutation in the donor, suggesting site-specific selection in vivo (Supplementary Fig. 10) . These results suggest that genetic-lineage targeting coupled with yeast display can be useful for antibody discovery against HIV-1 or other difficult pathogens for which bNAbs are reported to have specific genetic requirements 22, 23 .
Finally, we constructed a paired V H :V L library from 12 million peripheral B cells harvested 270 d after immunization with seasonal, trivalent inactivated influenza vaccine (IIV3) (ref. 24 ) when HA-specific B cells occur at a frequency of ~0.01% 25 . We isolated single yeast colonies after one round of sorting for antibody-expressing cells and four rounds of screening with Group 1 HA (18 clones) and separately, Group 2 HA (16 clones) included in IIV3 (Group 1: H1 from A/Solomon Islands/3/2006; Group 2: H3 from A/Wisconsin/67/2005); decreasing concentrations of antigen were used across rounds to increase selection stringency (Fig. 2g,h and Supplementary Fig. 11 ). Of these, 15/34 (44%) colonies encoded four unique antibody lineages to HA (one targeting H1 and three targeting H3) that bound to recombinant HAs with affinities ranging from 0.35 to 39.9 nM when expressed as IgGs ( Fig. 2i, Supplementary Fig. 12 and Supplementary  Table 5 ); an additional 7/34 colonies (21%) recognized HAs but with lower affinities. Two of the four antibodies reported in Figure 2i neutralized influenza with picomolar inhibitory concentrations (IC 50 ) ( Supplementary Fig. 13) .
The display of a properly folded, functional antibody repertoire in yeast constitutes a renewable resource for the isolation of human antibodies and also for repeated analyses of the antibody response based on properties such as affinity, epitope coverage (e.g., by sorting in the presence of competitor antibodies), and stability 15 b r i e f c o m m u n i c at i o n s surface display has been reported to have a lower expression bias relative to other microbial display technologies [13] [14] [15] , and the yeast display optimization reported here further ensured bona fide expression of human antibody repertoires. We expect native V H :V L antibodies to show superior selectivity and biophysical properties compared to randomly paired V H and V L antibodies isolated using other display platforms 9, 10 . Native antibody libraries displayed on yeast can be screened for antigens that bind to B-cell surface ligands (e.g., sialic acid 26 or CR2 (ref. 27) ) and are therefore not suitable for single-B-cell sorting, and also can be used to discover antibodies targeting insoluble antigens, including membrane proteins [28] [29] [30] .
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oNLINE MEtHods
Strain and media. The yeast strain AWY101 (MATα AGA1::GAL1-AGA1:: URA3 PDI1::GAPDH-PDI1::LEU2 ura3-52 trp1 leu2∆1 his3∆200 pep4::HIS3 prb1∆1.6R can1 GAL) (kind gift from Eric Shusta, University of Wisconsin-Madison) was used for library construction and screening. EBY100 (MATa AGA1::GAL1-AGA1::URA3 ura3-52 trp1 leu2∆1 his3∆200 pep4::HIS3 prb1∆1.6R can1 GAL) was used for initial native human antibody display. Yeast cells were maintained in YPD medium (20 g/l dextrose, 20 g/l peptone, and 10 g/l yeast extract); after library transformation, yeast cells were maintained in SDCAA medium (20 g/l dextrose, 6.7 g/l yeast nitrogen base, 5 g/l casamino acids, 8.56 g/l NaH 2 PO 4 .H 2 O, and 10.2 g/l Na 2 HPO 4 .7H 2 O). SGDCAA medium (SDCAA with 20 g/l galactose, 2 g/l dextrose) was used for library induction.
Antigens and antibodies. Recombinant Ebola virus glycoprotein with the mucin-like domain deleted (GP ∆muc ), and HIV-1 fusion peptide probe (VRC34-epitope scaffold-FP) and knockout scaffold probe (VRC34-epitope scaffold-KO) were produced as described previously 19, 31, 32 . Optimization of native human antibody display. Vectors encoding previously reported anti-influenza virus HA monoclonal antibodies with or without leucine zipper domains were transformed into EBY100 or AWY101 using a Frozen-EZ Yeast Transformation II kit (Zymo Research) 16 . After culturing in SDCAA to an OD 600 of 2 at 30 °C, Fab surface expression was induced by transferring cells to SGDCAA medium at OD 600 of 0.5. After 2 d of induction at 20 °C, 10 6 cells were collected and washed twice with PBS + 0.5% BSA + 2 mM EDTA, and incubated with 100 nM biotinylated hemagglutinin at room temperature for 30 min, followed by staining with 2 µg/ml anti-FLAG FITC and 2 µg/ml streptavidin-APC at 4 °C for 15 min. Cells were washed twice with ice-cold PBS + 0.5% BSA + 2 mM EDTA and analyzed on a FACS Aria II (BD Biosciences). Analysis of anti-EBOV GP ∆muc (c13c6, KZ52) and anti-HIV-1 FP (VRC34.01) antibodies was performed as above 19, 34, 35 , except 23 nM GP ∆muc -APC or 50 nM VRC34-epitope scaffold-FP-APC and 50 nM VRC34-epitope scaffold-KO-PE, respectively, were used for antigen staining.
Generation of natively paired V H :V L from peripheral B cells, library construction, yeast display and FACS screening.
Human subject protocols were approved by the NIAID Institutional Review Board. For anti-EBOV GP ∆muc antibody isolation, peripheral blood mononuclear cells (PBMCs) were isolated from a healthy human volunteer after immunization with a phase 1 Ebola GP vaccine (NCT02408913) 20 . The volunteer was first immunized with chimpanzee-derived replication-defective adenovirus encoding EBOV GP, then boosted 30 weeks and 5 d later with modified vaccinia Ankara encoding EBOV GP. Previous studies showed that plasmablasts in peripheral blood peak around 6 d post-boost immunization 36 . 10 ml of blood were collected and PBMCs isolated using Ficoll-Paque PLUS (GE Healthcare) 6 d post-boost. PBMCs were stained with a multi-color flow cytometry panel consisting of fluorophore-labeled antibodies against CD3 (Brilliant Violet 421, clone SP34-2, BD Biosciences), CD19 (PE-Cy7, clone HIB19, BD Biosciences), CD4 (Brilliant Violet 421, clone OKT4, BioLegend), CD8a (Brilliant Violet 421, clone RPA-T8, BioLegend), CD14 (Brilliant Violet 421, clone M5E2, BioLegend), CD20 (Brilliant Violet 605, clone 2H7, BioLegend), CD27 (Brilliant Violet 711, clone O323, BioLegend), and CD38 (Alexa Fluor 680, clone OKT10, customconjugated at the Vaccine Research Center, NIAID), and 7-aminoactinomycin D (7-AAD, Thermo Fisher Scientific) to exclude dead cells. 5,002 CD3 -CD4 -CD8 -CD14 -CD19 + CD20 -CD27 + CD38 + plasmablasts were isolated using a FACS Aria sorter (BD Biosciences) and subsequently used for emulsion V H : V L overlap extension RT-PCR.
For HIV-1 FP antibody isolation, PBMCs were collected from donor N123 on June 22, 2009 . This donor is a chronically HIV-1-infected individual enrolled in NIAID under a clinical protocol approved by the NIAID Institutional Review Board 37, 38 . This donor was diagnosed with HIV-1 in 2000. After more than nine years of infection, this donor showed a CD4 T cell count of 463 cells/ml and a plasma HIV-1 viral load of 4,920 RNA copies/ml. This donor was not on antiretroviral treatment. 1.42 × 10 6 peripheral B cells were isolated from 25 million PBMCs using a human B-cell selection kit (Stemcell Technologies).
For the isolation of influenza HA-specific antibodies, a healthy donor was vaccinated with a trivalent inactivated influenza vaccine (IIV3: A/Solomon Islands/3/2006, A/Wisconsin/67/2005, B/Malaysia/2508/2004) 24 . Subsequently, 270 d after vaccination, 1.2 × 10 7 B cells were isolated from blood leukapheresis using a human pan B-cell isolation kit (Miltenyi Biotec).
We used a flow-focusing nozzle to rapidly compartmentalize B cells in single-cell emulsion droplets, followed by single-B-cell lysis inside droplets and single-cell mRNA capture with oligo(dT)-coated magnetic beads 11, 12 . Overlap extension RT-PCR was then performed to link heavy and light chains using a Superscript III RT-PCR kit (Thermo Fisher Scientific) 11, 12 . We included NcoI and NheI restriction sites in the linker region of the overlap-extension RT-PCR primers that link V H and V L into an ~850 bp amplicon ( Supplementary  Table 3 ). For HIV-1 experiments, we also included additional primers specific to the VRC34 lineage ( Supplementary Table 4 ). For library construction, 100 ng of V H :V L cDNA was amplified under the following conditions with AccuPrime Pfx DNA polymerase (Thermo Fisher Scientific) to introduce NotI and AscI sites, respectively ( Supplementary Table 1 ): 2 min initial denaturation at 95 °C, denaturation at 95 °C for 20 s for 20 cycles, annealing at 60 °C for 20 s and extension at 68 °C for 60 s, final extension at 68 °C for 5 min. The DNA product was digested and ligated into pCT-VHVL-K1 (for V H :V κ libraries) and pCT-VHVL-L1 (for V H :V λ libraries), and transformed into electrocompetent E. coli for library cloning en masse. Plasmid DNA encoding V H : V L libraries was miniprepped, digested with NcoI and NheI, ligated with the bidirectional promoter, and transformed into E. coli again. The final library DNA was miniprepped, then amplified using the transformation primers ( Supplementary Table 1 ) to generate library inserts with homologous ends to NotI and AscI double-digested vectors, and then inserts were co-transformed into electrocompetent AWY101 together with the digested vectors to generate libraries via yeast homologous recombination 39 . Library sizes for EBOV, HIV-1 and flu repertoires were EBOV_κ: 2 × 10 7 , EBOV_λ: 10 7 , HIV-1_κ: 10 7 , HIV-1_λ: 9 × 10 6 , flu_κ: 7 × 10 7 , and flu_λ: 3 × 10 7 , respectively, as determined by colony counting.
For library screening, natively paired human V H :V L libraries were displayed on yeast by growing cells resuspended in SGDCAA medium at 20 °C for 2d to induce Fab expression. The fraction of Fab-expressing cells 2d post induction were consistent with previous reports for yeast displaying naïve human scFv 15 . For EBOV vaccinee and HIV-1 donor libraries, three rounds of sorting were performed against GP ∆muc , or VRC34-epitope scaffold-FP-APC and VRC34epitope scaffold-KO-PE, respectively. The VRC34-epitope scaffold-FP was designed to present the FP in an optimal conformation and provide a glycan in a similar context as that presented by the native HIV-1 trimer 19 . In the first round of screening, at least tenfold coverage in yeast clones relative to library size were labeled with 2 µg/ml anti-FLAG-FITC and either (i) 23 nM GP ∆muc -APC for isolating of EBOV GP ∆muc -specific antibodies, or (ii) 50 nM VRC34-epitope scaffold-FP-APC and 50 nM VRC34-epitope scaffold-KO-PE for the isolation of HIV-1 FP-specific antibodies. For EBOV antibody libraries, the PE channel was also included to correct for yeast autofluorescence. Cells were stained at room temperature for 30 min and washed twice with ice-cold PBS + 0.5% BSA + 2mM EDTA, then analyzed by FACS. FITC + APC + PEcells were selected and recovered in SDCAA medium at 30 °C. Subsequent screening rounds were performed similarly, except that for the EBOV GP antibody library, at least 5 × 10 5 cells were screened in rounds 2 and 3, and for HIV-1 FP antibody library, at least 10 7 cells were screened in rounds 2 and 3. Affinity binning of anti-EBOV GP ∆muc and anti-HIV-1 FP antibody repertoires was performed similarly as described 40 .
Influenza HA-specific antibodies were isolated following five total rounds of sorting (two rounds of MACS (magnetic-activated cell sorting) and three rounds of FACS enrichment for binding to fluorescent HAs) as follows. For the first round, at least tenfold coverage in yeast clones relative to library size were labeled with 2 µg/ml anti-FLAG-FITC at room temperature for 30 min. After washing, cells were labeled with anti-FITC microbeads (Miltenyi Biotec) at 4 °C for 15 min, and Fab-expressing cells were selected by MACS. For the second round of sorting, cells were labeled with 1 µM biotinylated recombinant HA (H1 A/Solomon Islands/3/2006, H3 A/Wisconsin/67/2005), and then selected with streptavidin microbeads (Miltenyi Biotec) using MACS as previously described 41 . Subsequently the library was screened using three rounds of FACS by labeling 5 × 10 6 cells with 2 µg/ml anti-FLAG-FITC together with 1 µM HA (first FACS round), 200 nM HA (second FACS round), or 40 nM HA (third FACS round), at room temperature for 30 min, followed by incubation with 2 µg/ml streptavidin-APC at 4 °C for 15 min before sorting.
Sequencing of the natively paired antibody repertoire from B cells was performed as previously described 42 . Bioinformatic analysis was performed as previously described 42 .
Recovery and expression of antibody clones from enriched libraries.
Yeast cells from the final round of sorting were plated on SDCAA plates. A minimum of ten colonies were selected following the last round of each screening campaign. Colony PCR was performed on heavy and light chain variable regions of each clone. Clones were sequenced, and the unique antibodies were named as project_name.YD.unique_clone_number. For antibody expression, restriction sites were incorporated for insertion into the VRC8400 IgG1, and Igκ or Igλ expression vectors (for anti-EBOV GP ∆muc and HIV-1 FP antibodies), or Gibson assembly was used to clone the variable regions into modified pcDNA3.4 IgG1, and Igκ or Igλ vectors (for anti-HA antibodies). Expi293 cells were co-transfected with heavy-and light-chain plasmids for each antibody, and secreted antibodies were purified on a Protein A column 43 . Fabs were produced by digestion of IgG1 with Lys-C Protease (Thermo Fisher Scientific) and separated from Fc using Protein A or Protein G columns.
For EBOV vaccinee libraries, the population of sorted FITC + Fab-expressing yeast cells in the first round of FACS were recovered in SDCAA medium at 30 °C. Plasmid DNA was extracted using high-efficiency yeast plasmid recovery protocols as reported previously 44 and V H genes in sorted libraries were PCR-amplified using primers that targeted the yeast expression plasmid vector backbone (2YDrec_heavy_Vfor_MSrev1: TCTCGTGGGCTCGGAG ATGTGTATAAGAGACAGNNNNCTGTTATTGCTAGCGTTTTAGCA, and 2YDrec_huIgH_Crev_MSfor1: TCGTCGGCAGCGTCAGATGTGTATAAGA GACAGNNNNAAGGCGCGCCTGTACTTGC). Libraries were prepped by an additional round of PCR-based primer extension and Illumina adaptor addition to incorporate unique DNA barcodes for each sample, and sequenced using the Illumina 2 × 300 bp MiSeq platform. Similarly, FACS-sorted yeast from EBOV vaccinee libraries analyzed for binding to GP ∆muc and FACSsorted yeast from HIV-1 donor libraries analyzed for binding to VRC34epitope scaffold-FP-APC were recovered, mini-prepped, and sequenced in the same way after each round of sorting to quantify V H gene clonal enrichment across library sorting rounds.
For determining the EBOV vaccinee antibody library display efficiency, the original plasmablast V H :V L repertoire underwent highly stringent quality filtering (≥15 CDRH3:CDRL3 reads, 96% CDRH3 nt clustering), and CDR-H3 nucleotide junctions were mapped to CDR-H3 junctions recovered in the FITC + Fab-expressing yeast library. Mapping was performed using usearch v5.2.32 with an exact nucleotide length match requirement and a 96% cutoff threshold for CDR-H3 junction nucleotide sequence match. For EBOV GP ∆muc library antibody discovery via NGS (next-generation sequencing) clonal lineage tracking, CDR-H3 amino acid sequences from NGS data sets that were enriched more than eightfold across multiple rounds of screening were synthesized, expressed in HEK293 cells, and tested for soluble binding to GP ∆muc as Fabs (EBOV.YD.05-EBOV.YD.08). Consensus sequences for NGS-discovered antibodies were generated based on exact CDR-H3 and CDR-L3 nucleotide junction matches between the originally paired V H :V L , separate V H , and separate V L sequencing libraries (before yeast display screening), as previously described for antibody discovery from paired heavy:light sequence data sets 42, 45, 46 . Briefly, consensus sequences were generated using usearch v5.2.32 from exact match reads to the CDR-H3 nucleotide or CDR-L3 nucleotide junctions for heavy or light chains, respectively, and plasmids containing antibody heavy and light chain sequences were expressed via transient transfection in HEK293 cells for soluble antibody generation as previously described 32 .
Affinity characterization. Binding kinetics of anti-EBOV GP ∆muc and anti-HIV-1 FP Fabs were determined using biolayer interferometry on a FortéBio Octet HTX instrument 32 . For EBOV GP ∆muc -targeting antibodies, AR2G biosensors were coupled with GP ∆muc (10 µg/ml in 10 mM acetate, pH 4.5) for 600 s. Typical capture levels after quenching with 1 M ethanolamine (pH 8.0) for 300 s were between 2 and 2.5 nm, and variability within the same protein did not exceed 0.25 nm. Biosensors were then equilibrated for 420 s in PBST-BSA (PBS + 1% BSA + 0.01% Tween + 0.02% sodium azide) before binding assessment of the Fab. Association of Fab was measured for 300-600 s and dissociation was measured for 300-600 s, both in PBST-BSA. Correction to subtract nonspecific baseline drift was carried out by subtracting the measurements recorded for a sensor loaded with unrelated antigen (HIV-1 gp120).
For HIV-1 FP-targeting antibodies, streptavidin biosensors were used to capture VRC34-epitope scaffold-FP at 0.5 µg/mL in PBST-BSA. Typical capture levels for FP probe were between 0.4 and 0.7 nm. Biosensors were then equilibrated for 60 s in PBST-BSA before binding assessment of the Fab. Association of Fab was measured for 150 s and dissociation was measured for 150 s, both in PBST-BSA. Correction to subtract non-specific baseline drift was carried out by subtracting the measurements recorded for a sensor loaded without Fab. All assays were performed with agitation set to 1,000 r.p.m. at 30 °C. Data analysis and curve fitting were carried out using the Octet analysis software, version 9.0. Experimental data were fitted using a 1:1 binding model for all experiments. Global analyses of the complete data sets, assuming binding was reversible (full dissociation), were carried out using nonlinear least-squares fitting allowing a single set of binding parameters to be obtained simultaneously for all concentrations used in each experiment.
For anti-HA IgGs, recombinant HAs (H1 A/Solomon Islands/3/2006, H3 A/Wisconsin/67/2005) 33 were immobilized in separate channels by aminecoupling at pH 6.0. BSA was immobilized in the reference channel, to correct for buffer effects and non-specific binding signal. All SPR measurements were performed in HBS-EP running buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% vol/vol surfactant P20; GE Healthcare). Serially diluted antibodies were injected in triplicates at 30 µl/min for 2 min and allowed a dissociation time of 10 min. The chip was regenerated after each binding event with 50 mM Tris, pH 11.5, with a contact time of 15 s. The resulting sensorgrams were fitted with a two-state model (with conformation change) using Biaevaluation 3.0 software. The K D values reported are the average of the three technical replicates ± s.d.
For EBOV GP ∆muc antibody cross-competition assays, 10 µg/mL of GP ∆muc was loaded onto Octet HTX biosensors using amine coupling (AR2G, FortéBio) for 600 s. The newly identified antibodies, the KZ52 antibody as a positive control 21 , and the isotype negative control (VRC01 (ref. 47)) were diluted to 50 µg/mL in PBST-BSA. Binding of competitor and analyte monoclonal antibodies (mAbs) were each assessed for 1,800 s. The assay was performed in duplicate with agitation at 1,000 r.p.m. at 30 °C. The percent inhibition (PI) was calculated by the equation: PI = 100 − [(probing mAb binding in the presence of competitor mAb)/(probing mAb binding in the absence of competitor mAb)] × 100.
Neutralization assays. For EBOV neutralization, GP-pseudotyped lentiviral particles expressing a luciferase reporter gene were produced as described previously 48 , and were incubated 1 h at 37 °C with serially diluted purified mAbs. HEK293T cells were infected with the lentivirus:mAb mixture for 72 h in presence of polybrene (5 µg/ml, Sigma-Aldrich). Luciferase expression was assessed with Bright Glo (Promega) using a Victor X3 Plate Reader (PerkinElmer). Cell infection was calculated relative to the negative control antibody VRC01.
HIV-1 neutralization was assessed in TZM-bl cells as described previously 19 . Briefly, 293T cells were co-transfected by a pSG3∆Env backbone and an HIV-1 Env expression plasmid to produce Env-pseudotyped virus stocks. Viruses were mixed with fivefold serially diluted mAbs starting at 50 µg/ml, and incubated at 37 °C for 1 h before being added to the cells. After incubation at 37 °C for 48 h, the supernatants were removed and the cells were lysed. Luciferase activity was measured. 50% inhibitory concentrations (IC 50 ) were determined as described 19 .
For flu neutralization, influenza pseudotyped lentiviral vectors expressing a luciferase reporter gene were produced as described 49 . Briefly, the following plasmids: 17.5 µg pCMV∆R8.2, 17.5 µg pHRCMV-Luc, 0.3 µg pCMV Sport/h TMPRSS2, and 1 µg CMV/R-HA and 0.125 µg corresponding CMV/R-NA of a given strain of influenza virus were transiently co-transfected into 15-cm tissue culture plate of 293T cells using Fugene6 (Promega). Cells were transfected overnight and replenished with fresh medium. Forty-eight hours later, supernatants were harvested, filtered through a 0.45-µm PES (polyethersulfone) membrane filter, aliquoted, and frozen at -80 °C. For neutralization assays, monoclonal antibodies at various dilutions were mixed with pseudoviruses and incubated at 37 °C for 1 h before adding to 293A cells in 96-well plates (10,000 cells per well). Seventy-two hours later, cells were lysed in cell culture lysis buffer (Promega, Madison, WI) before mixing with luciferase assay reagent (Promega). Light intensity was quantitated with a PerkinElmer microplate reader and antibody neutralization results, in lower light intensity. Corresponding author(s): George Georgiou John R. Mascola
Initial submission Revised version Final submission
Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity. 
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
This was not relevant to this study
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
This was not relevant to this study
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
